News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

APP Pharmaceuticals Announces Launch of Imipenem and Cilastatin for Injection, USP and Meropenem for Injection, USP



2/8/2012 6:52:38 AM

SCHAUMBURG, Ill.--(BUSINESS WIRE)--APP Pharmaceuticals, Inc., a Fresenius Kabi Company, announced today that it will launch both Imipenem and Cilastatin for Injection, USP and Meropenem for Injection, USP in the United States. APP will begin shipping Meropenem for Injection the week of February 13, 2012 with Imipenem and Cilastatin for Injection scheduled to ship in the next three to five weeks.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES